Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)

 Eliem Therapeutics Inc ELYM announced interim results from its ongoing Period 1 trial of ETX-155 for important
Therapeutics
Foghorn Therapeutics Announces To start with Affected person Dosed in First-in-Human Medical Trial of FHD-609
FHD-609 is a very first-in-class, really potent and selective protein degrader of BRD9 Foghorn’s to
Appili Therapeutics Experiences Economic and Operational Final results for Very first Quarter of Fiscal Calendar year 2022
HALIFAX, Nova Scotia, August 13, 2021–(Enterprise WIRE)–Appili Therapeutics Inc. (TSX:APLI OTCQX: APLIF) (the “Firm” or
Foghorn Therapeutics Delivers 2nd Quarter 2021 Company Update
— Very first Sufferers Dosed in Stage 1 Medical Trials of FHD-286, an Inhibitor of
Abeona Therapeutics Appoints Edward Carr as Main Fiscal Officer
NEW YORK and CLEVELAND, Aug. 10, 2021 (Globe NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO),
Trevi Therapeutics Announces Additions to the Senior Management Staff
Key Management Appointments Aid Enterprise Advancement as Guide Trials Transfer Towards Data NEW HAVEN, Conn.,
MONDAY DEADLINE: Investors with Sizeable Losses Have Opportunity to Direct the Frequency Therapeutics, Inc. Class Action Lawsuit
SAN DIEGO, July 29, 2021 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that
DEADLINE Subsequent Week: Investors with Sizeable Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Motion Lawsuit
SAN DIEGO, July 28, 2021–(Small business WIRE)–Robbins Geller Rudman & Dowd LLP announces that a
Future DEADLINE: Investors With Substantial Losses Have Possibility to Direct the Frequency Therapeutics, Inc. Course Motion Lawsuit
San Diego, California–(Newsfile Corp. – July 26, 2021) – The Frequency Therapeutics, Inc. (NASDAQ: FREQ)
Traders With Sizeable Losses Have Option to Direct the Frequency Therapeutics, Inc. Course Motion Lawsuit
San Diego, California–(Newsfile Corp. – July 22, 2021) – The Frequency Therapeutics, Inc. class action